“As the coronavirus outbreak intensified earlier this year, drugmaker Gilead Sciences sought and received an “orphan drug” designation for the antiviral drug remdesivir as a potential treatment for COVID-19. The orphan drug status gives a company a seven-year period of market exclusivity when it alone can sell and profit from treatment. But drugs only receive…